

# **Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice**

**Authors:** Sara A. Healy<sup>1</sup>, Charles Anderson<sup>1</sup>, Bruce J. Swihart<sup>2</sup>, Agnes Mwakingwe<sup>1</sup>, Erin E. Gabriel<sup>2,3</sup>, Hope Decederfelt<sup>4</sup>, Charlotte V. Hobbs<sup>1</sup>, Kelly M. Rausch<sup>1</sup>, Daming Zhu<sup>1</sup>, Olga Muratova<sup>1</sup>, Raul Herrera<sup>1</sup>, Puthupparampil V. Scaria<sup>1</sup>, Nicholas J. MacDonald<sup>1</sup>, Lynn E. Lambert<sup>1</sup>, Irfan Zaidi<sup>1</sup>, Camila H. Coelho<sup>1</sup>, Jonathan P. Renn<sup>1</sup>, Yimin Wu<sup>1&</sup>, David L. Narum<sup>1</sup>, Patrick E. Duffy<sup>1\*</sup>

**Affiliations:** <sup>1</sup>Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

<sup>2</sup>Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

<sup>3</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.

<sup>4</sup>Pharmacy Department. Clinical Center. National Institutes of Health, Bethesda, Maryland, USA.

\*Correspondence to: Patrick E. Duffy, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-8180, USA. [patrick.duffy@nih.gov](mailto:patrick.duffy@nih.gov)

<sup>&</sup>Current affiliation: PATH-Malaria Vaccine Initiative

**Conflict of interest statement:** The authors have declared that no conflict of interest exists.

## 22 **Abstract**

23 **Background.** Vaccines that block human-to-mosquito *Plasmodium* transmission are needed for  
24 malaria eradication and clinical trials have targeted zygote antigen Pfs25 for decades. We  
25 reported that a Pfs25 protein-protein conjugate vaccine formulated in alum adjuvant induced  
26 significant serum functional activity in both US and Malian adults. However, antibody titers  
27 declined rapidly, and transmission-reducing activity required four vaccine doses. Functional  
28 immunogenicity and durability must be improved before advancing TBV further in clinical  
29 development. We hypothesized that the pre-fertilization protein Pfs230 alone or in combination  
30 with Pfs25 would improve functional activity.

31 **Methods.** Transmission-blocking vaccine candidates based on gamete antigen Pfs230 or Pfs25  
32 were conjugated with Exoprotein A, formulated in Alhydrogel<sup>®</sup>, and administered to mice, rhesus  
33 macaques, and humans. Antibody titers were measured by ELISA and transmission-reducing  
34 activity was assessed by the Standard Membrane Feeding Assay.

35 **Results.** Pfs25-EPA/Alhydrogel<sup>®</sup> and Pfs230D1-EPA/Alhydrogel<sup>®</sup> induced similar serum  
36 functional activity in mice, but Pfs230D1-EPA induced significantly greater activity in rhesus  
37 monkeys that was enhanced by complement. In U.S. adults, two vaccine doses induced  
38 complement-dependent activity in 4 of 5 Pfs230D1-EPA/Alhydrogel<sup>®</sup> recipients but no  
39 significant activity in five Pfs25-EPA recipients, and combination with Pfs25-EPA did not  
40 increase activity over Pfs230D1-EPA alone.

41 **Conclusion.** The complement-dependent functional immunogenicity of Pfs230D1-EPA  
42 represents a significant improvement over Pfs25-EPA. The rhesus model is more predictive of  
43 the functional human immune response to Pfs230D1 than is the mouse model.

44 **Trial Registration.** ClinicalTrials.gov NCT02334462

45       **Funding.** This work was supported by the Intramural Research Program of the National Institute  
46       of Allergy and Infectious Diseases, National Institutes of Health.

47

48

49

## 50 **Introduction**

51 The world has achieved significant strides in malaria control with roughly half of countries  
52 having eliminated the disease, but existing tools failed to achieve elimination despite  
53 comprehensive application in African settings (1, 2), and recent progress to reduce malaria cases  
54 has stalled globally and been reversed in some areas (3). Vaccines have been essential for  
55 elimination of infectious agents like smallpox, polio, and measles by halting their onward  
56 transmission, conferring major benefits to human health and economies (4-6). Malaria  
57 transmission-blocking vaccines (TBV) were conceived in the 1970's as a tool to interrupt  
58 parasite transmission with antibodies that attack sexual stage parasites in the mosquito vector (7,  
59 8). Monoclonal antibodies to mosquito sexual stage (gamete) parasites were used to identify  
60 candidate TBV antigens, including gamete surface proteins P230 and P48/45 first expressed by  
61 gametocytes in human blood (9), and zygote surface proteins P25 and P28 expressed only post-  
62 fertilization in the mosquito host (10, 11). These antigens are multi-domain cysteine-rich proteins  
63 and generally difficult to produce as properly folded recombinant protein. *P. falciparum* P25  
64 (Pfs25) antigen was the first expressed as recombinant protein (12) and has remained the leading  
65 TBV candidate for three decades. In preclinical studies, Pfs25 vaccines have induced equal or  
66 greater serum activity versus other candidate antigens or antigen combinations (13, 14).

67 While earlier P25 candidates failed to meet safety or activity criteria to advance in the clinic (15,  
68 16), we recently reported that a Pfs25 protein-protein conjugate vaccine formulated in alum  
69 adjuvant induced significant serum functional activity in both US (17) and Malian adults (18).  
70 However, few vaccinees developed transmission reducing activity (TRA) >50% or significantly  
71 increased their TRA after 2 or 3 doses of Pfs25 vaccine: 2/17 subjects after 2 doses and 2/15  
72 after 3 doses in US adults (17); and no significant activity was seen in vaccinees (versus

73 comparators) after 3 doses in Malian adults (18). In each study, significant functional activity  
74 required four vaccine doses, and antibody titers declined rapidly, suggesting functional  
75 immunogenicity and durability must be improved before advancing TBV further in clinical  
76 development. We hypothesized that the pre-fertilization protein Pfs230 alone or in combination  
77 with Pfs25 would improve functional activity.

78 To assess the contribution of Pfs230 to a TBV, a fragment (Ser<sub>542</sub> to Gly<sub>736</sub>) encompassing  
79 domain 1 of Pfs230 cloned and expressed in *P. pastoris* (Pfs230D1, previously referred to as  
80 Pfs230D1M) as described in (19) was chemically conjugated to EPA (20), a non-toxic mutant of  
81 exoprotein A from *P. aeruginosa* using methods previously described for development of the  
82 Pfs25-EPA vaccine (21). Here, we compare Pfs230D1-EPA to our benchmark TBV (Pfs25-EPA)  
83 formulated in alum in three models (mice, nonhuman primates, and humans) and assess their  
84 activity in combination.

85

## 86 Results

87 To confirm the benefit of conjugation of Pfs230D1, groups of CD-1 mice were immunized twice  
88 (0, 28 days) by intramuscular injection with either Pfs230D1 or Pfs230D1-EPA, both formulated  
89 in Alhydrogel<sup>®</sup>, which was the clinical formulation. Antibody titers induced by Pfs230D1-EPA  
90 were ~100-fold greater than titers induced by Pfs230D1 monomer (**Fig. S1**). For clinical  
91 development planning, we assessed Pfs230D1 and Pfs25 for their relative capacities to induce  
92 functional antibodies, to determine if one antigen should be prioritized over the other for clinical  
93 testing. Initial dose ranging studies with Pfs230D1-EPA were performed in mice in order to  
94 determine appropriate doses to use for future mouse experiments (**Fig. S2**); subsequently all mice  
95 were immunized with doses ranging from 0.1 to 3 µg per immunization 28 days apart.

96 Data were collated from multiple experiments using both BALB/c and CD-1 outbred mice with  
97 head-to-head comparisons of Pfs25-EPA/Alhydrogel<sup>®</sup> and Pfs230D1-EPA/Alhydrogel<sup>®</sup> for  
98 functional antibody activity assessed by Standard Membrane Feeding Assay (SMFA) of *P.*  
99 *falciparum* strain NF54 gametocytes to *Anopheles stephensi* mosquitoes (**Fig. 1A**). Parasite  
100 Transmission-Reducing Activity (TRA, reduction in mean oocyst count per mosquito versus  
101 control antibody) was plotted against ELISA titers for 4 separate experiments, containing 3  
102 immunizing doses in each experiment. There was a titer-dependent positive correlation for both  
103 antigens (Pfs230D1,  $r=0.68$   $P=0.02$ ; Pfs25,  $r=0.58$   $P=0.06$ ), with high TRA achieved at the  
104 higher titers with both antigens, but with no difference between Pfs25 and Pfs230D1.

105 Multiple publications have shown a dependency on active complement for anti-Pfs230 inhibition  
106 in preclinical studies (22-24). Therefore, serum samples from BALB/c mice immunized with  
107 cGMP Pfs230D1-EPA/Alhydrogel<sup>®</sup> were tested by SMFA when mixed with intact or heat-  
108 inactivated human sera. Again, sera from mice immunized with Pfs230D1-EPA inhibited oocyst

109 development in a dose-dependent manner and was not significantly different from that of Pfs25-  
110 EPA sera (**Fig. S3, Table S1**). In the absence of active human complement in a dose titration  
111 experiment, antibodies against both antigens blocked equally well.

112 Since mouse studies did not distinguish one antigen (Pfs25 or Pfs230D1) as superior over the  
113 other for functional activity and therefore their prioritization for clinical testing, we hypothesized  
114 a non-human primate model may reveal quantitative differences in activity of the two vaccine  
115 candidates. We conducted a vaccine study in rhesus macaques using the clinical Alhydrogel®  
116 formulation and doses of Pfs230D1-EPA (40 µg Pfs230D1) and Pfs25-EPA (47 µg Pfs25)  
117 administered by intramuscular injection on a 0, 2, 6-month schedule, similar to a typical human  
118 clinical trial regimen and schedule. Antibody titers were monitored to confirm Pfs25 and  
119 Pfs230D1 immunogenicity (**Fig. 1B, Fig. S4A, C**). Sera from peak titers, collected two weeks  
120 after the third dose (day 182), were used in SMFA to assess function in the presence of intact  
121 human sera (**Fig. 1B, Fig. S4B, D, and Table S2**). Anti-Pfs25 immune sera demonstrated overall  
122 modest inhibition of oocyst development, similar to previous preclinical and clinical experience.  
123 In contrast, anti-Pfs230D1 had potent inhibitory activity, with all samples reducing oocyst  
124 density by greater than 80%, and 3/6 achieving greater than 50% reduction in the prevalence of  
125 infected mosquitoes, referred to as Transmission-Blocking Activity (TBA).

126 To measure the contribution of complement to the activity, serum samples from the Pfs230D1  
127 group were tested again by SMFA, in the presence or absence of complement (**Fig. 1C and**  
128 **Table S3**). Distinct from observations in mice, activity was significantly diminished in the  
129 absence of complement ( $p=0.03$ , Wilcoxon Matched-Pairs signed rank test for difference  
130 between groups). However, even without complement, 5/6 monkeys had greater than 50% TRA,

131 suggesting rhesus react to an epitope that blocks biological function. Thus, the rhesus model  
132 indicated that Pfs230D1 was a superior vaccine target, in part due to the activity of complement.  
133 After establishing that Pfs230D1-EPA/Alhydrogel<sup>®</sup> or Pfs25-EPA/Alhydrogel<sup>®</sup> were well-  
134 tolerated, immunogenic, and induced functional activity in preclinical models, a phase 1 first-in-  
135 human clinical trial was initiated to assess safety and to compare Pfs25-EPA/Alhydrogel<sup>®</sup>,  
136 Pfs230D1-EPA/Alhydrogel<sup>®</sup>, or a combination of the two, before advancing either candidate to  
137 field trials. US adults were vaccinated in a staggered manner for safety. Five subjects per arm  
138 received two immunizations (0, 28 days) with Pfs230D1-EPA/Alhydrogel<sup>®</sup> or Pfs25-  
139 EPA/Alhydrogel<sup>®</sup> or both co-administered in separate arms. Overall, vaccinations with all doses  
140 of Pfs25-EPA/Alhydrogel<sup>®</sup> (16 µg; 47 µg), Pfs230D1-EPA/Alhydrogel<sup>®</sup> (5 µg; 15 µg; 40 µg),  
141 and the combination (Pfs25 + Pfs230D1: 16 µg + 15 µg; 47 µg + 40 µg) were well-tolerated with  
142 minimal local and systemic reactogenicity reported and no serious adverse events (**Table S4**).  
143 Pfs25-EPA/Alhydrogel<sup>®</sup> elicited anti-Pfs25 antibodies at the high dose but not at the low dose  
144 (**Fig. 2B** compared to **2A**, p=0.03) while titers against Pfs230D1 were not dose-dependent (**Fig.**  
145 **2C, D, E**). Combining low dose Pfs25-EPA/Alhydrogel<sup>®</sup> with low dose Pfs230D1-  
146 EPA/Alhydrogel<sup>®</sup> elicited significantly higher anti-Pfs25 titers than low dose Pfs25-  
147 EPA/Alhydrogel<sup>®</sup> alone (**Fig. 2F** compared to **2A**, p=0.01); this effect was not observed with  
148 high dose vaccine (**Fig. 2G** compared to **2B**, p=0.12), and there was no potentiating effect of  
149 vaccine combinations on anti-Pfs230 titers. Interestingly, anti-Pfs230 titers were measurable  
150 even at the lowest Pfs230D1-EPA dose of 5 ug (**Fig 2C**), unlike the Pfs25-EPA vaccine (18),  
151 suggestive of better intrinsic immunogenicity.  
152 Sera from peak titers two weeks after the second dose in the high dose groups were measured for  
153 functional activity (TRA and TBA) by SMFA. In general, TRA are used to compare results from



154 different studies owing to consistency between assays, while TBA varies between assays based  
155 on parasite infectivity to mosquitoes (25). Consistent with previous published data (17) and with  
156 preclinical studies, two doses of Pfs25-EPA did not induce titers sufficient to reduce  
157 transmission (**Fig. 3A and Table S5**). However, aligning with the results seen in rhesus,  
158 Pfs230D1 induced high functional activity in humans. TRA was >90% in 2/5 individuals from  
159 the Pfs230D1-EPA arm (99%, 98%) and > 50% TRA in 2 others (73%, 62%), versus the Pfs25  
160 group in which 0/5 individuals had TRA>50%, representing a significant improvement of  
161 Pfs230D1-EPA over the benchmark Pfs25-EPA candidate (Fishers exact test,  $p<0.05$ ). In the  
162 Pfs25 + Pfs230D1 combination group, one individual had 90% and one had 65% TRA. TRA  
163 correlated well with anti-Pfs230D1 titers ( $r=0.77$ ,  $p=0.013$ ) but not anti-Pfs25 titers (**Fig 3B-C**),  
164 demonstrating that the functional activity is due to the Pfs230D1 vaccine. Titers achieved after 2  
165 doses of Pfs25 vaccine were similar in two previous studies in malaria-naïve US individuals  
166 (GM EU=147) (17) and malaria-exposed individuals in Mali (GM EU=93.1) (18) as in this study  
167 (GM EU=160.1), when comparing individuals who received the same vaccine dosage.  
168 Functional Pfs25 activity was also similar between the prior US study (17) and this study, with  
169 few (2/17) or no (0/5) individuals with serum TRA>50%, respectively, after 2 vaccine doses;  
170 serum TRA was not measured after vaccine dose 2 in the Mali field trial (18) and so cannot be  
171 compared to the current study.

172 Again, as seen in the non-human primate model, dependency on complement was confirmed  
173 with the Pf230D1 immune sera samples, as heat-inactivation of serum complement significantly  
174 reduced ( $p=0.009$ , Wilcoxon matched-pairs signed rank test), but did not completely eliminate,  
175 functional activity (**Fig. 4A, B and Table S6**). Sera from two individuals who received the  
176 vaccine combination appeared to increase parasite transmission to mosquitoes after heat-

177 inactivation (**Fig. 4D**); enhancement of *P. vivax* transmission has also been observed with  
178 naturally acquired antibodies or monoclonal antibodies used at low doses in membrane feeding  
179 assays (26). Naturally acquired serum transmission-enhancing activity has been observed against  
180 both *P. vivax* and *P. falciparum* (26-28), and this enhancing activity has been most apparent in  
181 heat-inactivated sera (27). While this enhancing activity has not previously been associated to  
182 Pfs230 antibodies in the absence of complement, our results echo these earlier findings.

183

184

## 185 **Discussion**

186 A transmission blocking vaccine could play a pivotal and unique role in malaria elimination  
187 efforts, by inducing durable immune responses that interrupt human-to-mosquito malaria  
188 transmission over an extended period of time. In our earlier clinical trials, the leading TBV  
189 candidate Pfs25 induced functional activity at peak antibody titers, but the activity was lost  
190 rapidly as titers decreased (17, 18). Here, we sought to increase TBV activity and durability by  
191 combining the post-fertilization antigen Pfs25 with the pre-fertilization antigen Pfs230D1. We  
192 found that Pfs230D1 was significantly more potent than Pfs25 as a vaccine, and the addition of  
193 Pfs25 to Pfs230D1 did not appear to improve on this activity. The superior activity of Pfs230D1  
194 over Pfs25 was predicted by preclinical studies in rhesus but not in mice and was largely  
195 explained by complement-dependent activity seen with monkey and human but not rodent  
196 antibody. Pfs230 or Pfs230 combination vaccines warrant further evaluation in field studies to  
197 assess their potential as a tool for malaria elimination as do adjuvants that increase levels and  
198 durability of functional antibody (29), particularly complement-fixing antibody isotypes.

199 TBV candidate antigens including Pfs230 have been challenging to prepare as properly folded  
200 proteins, owing to their cysteine-rich sequence and highly folded structure. Importantly,  
201 functional antibodies against these antigens commonly target conformation-dependent epitopes  
202 (19). The Pfs230 extracellular fragment includes 14 domains with 6-cys structure, a motif that  
203 has been particularly difficult to reproduce as recombinant antigen. Earlier studies showed that a  
204 Pfs230 polypeptide (Pfs230-C, amino acids 443-1132) encompassing an upstream region,  
205 domain 1 through 3, and 9 amino acids in domain 4 (30) or a polypeptide (Pfs230D1-2)  
206 encompassing an upstream region, domain 1 through 2 (19), induces functional antibodies in  
207 animal studies Here, we used *Pichia* expression system to generate properly folded Pfs230

208 domain 1 which induced more potent antibodies in rabbits compared to the Pfs230D1-D2  
209 polypeptide in the *ex vivo* SMFA (19), after prior success expressing full-length extracellular  
210 Pfs25 in *Pichia* (31) that induced functional antibodies in human studies (17). Our preclinical  
211 studies consistently demonstrated *Pichia*-expressed Pfs230D1 reacted to conformation-  
212 dependent functional monoclonal antibodies (19) and induced functional IgG in immunized  
213 animals.

214 Recent studies in mice suggested that Pfs25 immunogens were similar (13) or superior (14) to  
215 Pfs230 immunogens for inducing functional antibodies that block parasite transmission. In mice,  
216 we similarly found no significant differences in the ability of Pfs25 and Pfs230D1 recombinant  
217 immunogens prepared as conjugate nanoparticle vaccines to induce antibody activity in mice.  
218 However, our studies in monkeys suggested that the Pfs230D1 immunogen was significantly  
219 more potent for inducing serum functional activity. The difference between models can be  
220 explained at least partly by the complement-dependent nature of Pfs230-induced activity, which  
221 was pronounced in assays with monkey but not mouse antibody. Early studies using mouse  
222 monoclonal antibodies raised against native Pfs230 on gametes revealed functional antibodies  
223 restricted to IgG2a and IgG2b subclasses, with complement-mediated lysis being the putative  
224 mechanism of transmission blockage (22-24) with the exception of the murine mAb 4F12,  
225 isotype IgG1 which has been crystallized in complex with Pfs230D1 (32) and effectively blocks  
226 transmission independent of complement (19).

227 We examined antibody subclasses and isotypes to assess the role of complement-fixing antibody.  
228 In a previous study, we showed that mice immunized with Pfs230D1 showed a dominant IgG1  
229 isotype response (33) which is non-complement-fixing in mice. In the present study, we  
230 measured Pfs230D1-specific antibody isotypes in sera from rhesus macaques that received either

231 Pfs230D1-EPA/Alhydrogel® alone or Pfs25-EPA/Alhydrogel® + Pfs230D1-EPA/Alhydrogel®  
232 combination, two weeks after the second and third vaccinations (**Fig. S5**); and from human  
233 vaccinees 2 weeks after the second vaccination (**Fig. S6**). In both rhesus and humans, we  
234 observed that IgG1, which has the highest complement-fixing ability, was the dominant isotype  
235 induced, while the non-complement fixing IgG2 and IgG4 were significantly lower. Two human  
236 vaccinees produced appreciable amounts of IgG3 which is also complement-fixing. Pfs230-  
237 specific IgM, which also have complement-fixing properties, was readily detected in 4 of the 5  
238 vaccinees but they were consistently lower than the IgG1 isotype in all samples. We surveyed  
239 Day 84 sera for five subjects that had TRA on Day 56, and significant functional activity  
240 persisted for 4/5 subjects (**Fig. S7A**). We compared IgG and IgM purified from Day 84 sera of  
241 two subjects (Subjects #7 and #10) in SMFA, and oocyst counts were significantly lower in the  
242 presence of IgG than IgM (for Subject #7,  $p = 0.042$ ; for Subject #10,  $p = 0.006$ ; for both  
243 subjects combined,  $p = 0.001$ , **Fig. S7B**). Both serum and IgG from Subject #7 were tested for  
244 membrane attack complex (MAC) formation on gametes, showing MAC formation in assays  
245 using intact but not heat-inactivated sera (**Fig. S7C, D, E, F**). These results are consistent with  
246 recent evidence that human monoclonal antibodies we generated from Pfs230D1 vaccinees also  
247 induce MAC formation on gametes in the presence of intact but not heat-inactivated sera (34).  
248 Of note, mouse polyclonal sera induced by vaccination with an alum-based adjuvant conferred  
249 activity in the absence of the complement pathway. Additionally, rhesus immune sera  
250 significantly reduced transmission in the absence of complement, demonstrating other  
251 complement-independent mechanisms, such as neutralization. Indeed, in the clinical trial,  
252 function in one subject was not completely ablated in the absence of complement (**Fig. 4B**). We

253 are currently exploring mechanisms by which rodent mAb 4F12 might neutralize gametes in the  
254 absence of complement activity.

255 Our initial goal for the human studies was to examine whether a combination of Pfs25 with the  
256 pre-fertilization antigen Pfs230D1 was safe and might induce more potent and longer-lived  
257 activity than Pfs25 alone. In previous rodent studies, a combination of yeast-expressed Pfs25 and  
258 Pfs28 induced greater activity than either antigen alone (35), but combinations of Pfs25 and  
259 Pfs28 or of Pfs25 and Pfs230-C delivered as virus-vectored vaccines did not yield additional  
260 activity (14). Ultimately, each antigen combination must be tested empirically for positive or  
261 negative interference in humans. Here, we observed that Pfs230D1 alone formulated in  
262 Alhydrogel® (which has relatively modest immunopotentiating activity) could induce functional  
263 serum activity after only two doses in some individuals, suggesting vaccine activity could be  
264 enhanced by increasing the number of doses or by alternative adjuvants. Further, the addition of  
265 Pfs25 to Pfs230D1 during immunization did not provide additional activity. We are currently  
266 evaluating alternative adjuvants for their ability to enhance TBV activity, by increasing antibody  
267 titers and durability particularly for complement-fixing IgG subclasses.

268 Taken together, the data show two conclusions: 1) Pfs230D1 is a superior transmission-blocking  
269 antigen to Pfs25, and 2) the rhesus model is more predictive of the functional human immune  
270 response to Pfs230D1 than is the mouse model. The results from these studies yield valuable  
271 information for future studies to understand immune responses to Pfs230D1 and how  
272 improvements in vaccine development may lead to a licensed TBV.

273

274 **Methods**

275 Animal Studies

276 Five to 8-week-old naïve, female BALB/c or CD-1 mice were purchased from Taconic  
277 Laboratories (Hudson, NY) and maintained at a facility at the NIH. Immunizations were  
278 performed by either intraperitoneal or intramuscular (i.m.) injection in the anterior tibialis in a  
279 volume of 50 µL using a standard day 0 and day 28 regimen. *Macaca mulatta* (rhesus) were  
280 randomized by age, sex, and weight, and were maintained in an AAALAC accredited NIAID  
281 facility. Vaccinations were performed on days 0, 56, and 168 by intramuscular injection in a  
282 volume of 0.6 mL (Pfs25-EPA/Alhydrogel) or 0.8 mL Pfs230D1-EPA/Alhydrogel) in the leg,  
283 alternating legs for boosting injections.

284

285 Clinical Study Procedures

286 The clinical study was designed as an open label, dose escalation study to examine the safety and  
287 immunogenicity of Pfs230D1-EPA/Alhydrogel<sup>®</sup> and Pfs25M-EPA/Alhydrogel<sup>®</sup> alone or co-  
288 administered. The initial open-label dose-escalating, two-dose regimen (0, 1 month; n=5/group)  
289 was performed in the US prior to a larger double-blinded study conducted in Mali. Participants  
290 were sequentially enrolled in the following manner. No blinding or placebo arms were  
291 implemented. No randomization occurred.

292

293 ELISA

294 Immulon 4 HBX flat bottom microtiter plates (Dynex Technologies) ELISA plates were coated  
295 with 1 µg/ml of antigen in a volume of 100 µL per well in carbonate coating buffer (pH 9.6)  
296 overnight at 4°C. After blocking in 5% skim milk in TBS blocking buffer in a volume of 320 µL  
297 per well for 2 hrs, samples were serially diluted in TBS/5% milk and plated in triplicate in a

298 volume of 100  $\mu$ L per well and incubated at room temperature for 2 hours. Plates were washed 4  
299 times and alkaline phosphatase labeled goat anti-mouse IgG (H+L), goat anti-human IgG (H+L),  
300 or goat anti-monkey phosphatase labeled secondary antibody (Seracare Life Sciences) was added  
301 in a volume of 100  $\mu$ L per well and incubated at room temperature for 2 hours. After washing 4  
302 times, dissolved phosphatase substrate tablets (Sigma) were added in a volume of 100  $\mu$ L per  
303 well and plates were incubated for 20 minutes before optical densities (OD) were measured with  
304 a Spectramax 340PC (Molecular Devices). Each ELISA plate contained an internal serum  
305 standard from which a four-parameter curve was calculated with Softmax software. According to  
306 laboratory SOP, any samples for which ELISA results from triplicate wells exceeded a pre-  
307 specified CV were repeated. ELISA Units were assigned to test samples based on the sera  
308 dilution that gave an OD of 1.0, adjusted to the internal standard. For the Pfs230 isotyping  
309 assays, similar procedures were followed and the list of detecting antibodies utilized are listed in  
310 Supplementary table S7.

311

### 312 Transmission Blocking and Reducing Activity

313 Transmission blocking activity (TBA, reduction in infection prevalence) and transmission  
314 reducing activity (TRA, reduction in infection intensity) of the sera were tested by an *ex vivo*  
315 standard membrane feeding assay (SMFA) as described previously (13). Briefly, an *in vitro* 14-  
316 16 day old gametocyte culture of *P. falciparum* (NF54 line) was evaluated for stage V  
317 gametocytes (>0.5%) and the presence of exflagellation centers observed at 400X magnification  
318 (>1 per field). The culture was diluted with washed O+ red blood cells (RBCs) from a malaria  
319 naïve donor (Interstate Blood Bank, Memphis, Tennessee) to achieve 0.12%  $\pm$  0.05%  
320 concentration of Stage V gametocytes. For each sample, 100  $\mu$ L of the pelleted diluted culture



321 (100% hematocrit) was mixed with 160  $\mu\text{L}$  of test serum. For human sera samples, 160  $\mu\text{L}$  was  
322 used neat; for rhesus sera samples, 60  $\mu\text{L}$  of test sera was mixed with 100  $\mu\text{L}$  of a pool of naïve  
323 human AB<sup>+</sup> sera; for mouse sera samples, 20 or 30  $\mu\text{L}$  of test sera was mixed with 130  $\mu\text{L}$  of  
324 pooled naïve sera. All samples were immediately fed to pre-starved (~24 hours) 3-8 day old  
325 *Anopheles stephensi* (Nijmegen strain) mosquitoes through a Parafilm<sup>®</sup> membrane stretched  
326 across a glass mosquito feeder kept warm by a circulating water membrane at 40°C. Test sera  
327 were not heat-inactivated. Post feeding, mosquitoes were maintained for 8 days at 27°C and 80%  
328 humidity conditions to allow for the development of parasites. Infectivity was measured by  
329 dissecting at least 20 gravid mosquitoes per sample, staining the midguts with 0.05%  
330 mercurochrome solution in water for 20 minutes and counting the number of oocysts on each  
331 midgut. The feeding experiment was not analyzed unless the average oocyst count in the assay  
332 control mosquitoes (at least 20 dissected mosquitoes fed with naïve heat-inactivated serum) was  
333 more than four. The TBA and TRA are calculated by the following formulas:

$$334 \quad TRA = 100 \times \left( \frac{\text{Mean Oocyst Number}_{neg\ ctrl} - \text{Mean Oocyst Number}_{test}}{\text{Mean Oocyst Number}_{neg\ ctrl}} \right)$$

335 and

$$336 \quad TBA = 100 \times \left( \frac{\text{Mean No. Inf. Mosquito}_{neg\ ctrl} - \text{Mean No. Inf. Mosquito}_{test}}{\text{Mean No. Inf. Mosquito}_{neg\ ctrl}} \right)$$

337 where the negative control (*neg ctrl*) feed used pooled pre-vaccination sera from all subjects.  
338 Each sample from monkeys or humans that received Pfs230 or Pfs230 + Pfs25 vaccine was  
339 tested in two independent feeding experiments and these two TRA values were averaged to  
340 obtain a single subject level TRA for a given time point.

341

342 Immunofluorescence assay to assess the deposition of the membrane attack complex (MAC)

343 Formation of membrane attack complex (MAC) and further activation of the complement system  
344 were assessed using Immunofluorescence of live female gamete parasites. Briefly, 5 mL of a  
345 *Plasmodium falciparum* NF4 gametocyte stage V culture were centrifuged at 2,000 rpm for 5  
346 minutes and added to an exflagellation medium containing 900  $\mu$ L of RPMI, 100  $\mu$ L of PBS and  
347 1  $\mu$ L of xanthurenic acid, then left for 1.5 hours at room temperature. Cells were resuspended in  
348 5 mL of RPMI and applied to a 15 mL Nycodenz gradient (16%, 11% and 6%), then centrifuged  
349 at 7,000 x g for 30 minutes. Parasites located in the interface between 6% and 11% were  
350 collected into 50 mL of RPMI and spun down at 2,000 x g for 10 minutes. Parasites were then  
351 incubated with serum or 100  $\mu$ g/mL of total IgG previously purified from subject 30G and  
352 diluted in PBS. IgG1 isotype control with heavy and kappa chains was purchased from Creative  
353 Biolabs. The suspension was incubated at 37° C for 45 minutes with either 50  $\mu$ L of intact sera or  
354 sera heat-inactivated at 56°C, both obtained from US healthy donor. Subject serum was used  
355 directly without supplementation. During the incubation the tubes were gently mixed every 10  
356 minutes to facilitate C5b-9 and C5b-8 deposition on cells. Two mL of cold PBS were used to  
357 stop the reaction and to wash the cells. Suspension was centrifuged at 500 x g for 5 minutes and  
358 the pellet was then incubated with 10 $\mu$ g/mL of the mAb anti-C5b-9 + C5b-8 (Abcam, ref  
359 ab66768) for 2 hours on ice. Cells were washed with PBS, centrifuged at 500 x g for 5 minutes  
360 and stained with Hoechst 33342 Solution (Thermo Fisher) diluted at 1:20,000 for 8 minutes and  
361 further washed with PBS. Cells were kept in parasite culture media until the imaging was  
362 performed in a TCS SP8 MP microscope (Leica, Wetzlar, Germany) at 37°C. Quantification  
363 analyses was performed assessing the mean fluorescence per nuclei stained.

364

365 Statistics

366 All statistical tests were performed using Prism v7.0 by GraphPad Software, Inc. Pearson's  
367 correlation coefficient for the pairs of log-titer and TRA stratified by titer type were conducted  
368 for Figure 1A. Figure 2, Day 42 values of panel A vs F, B vs G, and A vs B were conducted by  
369 separate Wilcoxon rank sum tests with continuity correction. Figure 2 panels C vs D vs E were  
370 compared with a Kruskal-Wallis rank sum test. Figure 3A showcases 15 Kruskal Wallis tests  
371 (each animal compared with the naïve-pool as a control) with a Dunn-Bonferroni adjustment.  
372 Spearman's coefficient and exact p-values were calculated for both Figure 3B and Figure 3C.  
373 Figures 4A-D showcase Wilcoxon matched pairs signed-rank tests; each panel had 5 pairwise  
374 tests performed. Asterisks indicate  $p < 0.05/5 = 0.01$ . Figure S1 reports exact p-values for each  
375 of 3 Mann-Whitney tests. Figure S3 (and Table S1) displays 6 Kruskal Wallis tests performed  
376 for intact sera where each comparison involves the control and the p-values are Dunn-Bonferroni  
377 corrected. The same procedure was repeated for the Hi-Sera group with a different control in  
378 Figure S3. Figure S4 (and Table S2) display the results for 12 pre-vac vs post-vac Wilcoxon  
379 matched-pairs signed rank tests. Table S3 contains the results of 6 intact vs heat-inactivated  
380 Wilcoxon matched-pairs signed rank tests.

381

### 382 Study Approval

383 *Animal Studies.* All animal procedures were performed according to protocols approved by the  
384 NIAID and NIH Animal Care and Use Committee. All procedures were in accordance with the  
385 Guide for the Care and Use of Laboratory Animal Reports NIH 85-23.

386

387 *Human Ethics Statement.* This open label phase 1 trial was performed at the National Institutes  
388 of Health (NIH) Clinical Trial Center in Bethesda, MD. The study was conducted under an

389        investigational new drug application (IND) with the US Food and Drug Administration  
390        (#16251). The protocol was approved by the Institutional Review Board (IRB) of the National  
391        Institute of Allergy and Infectious Diseases (NIAID) and under trial investigation number at  
392        ClinicalTrials.gov (NCT02334462). All participants gave written informed consent in order to  
393        participate in the study.  
394

395 **Author contributions**

396 SAH, CA, EEG, KMR, YW, PED designed and conceptualized the study. KMR, DZ, RH, PVS,  
397 NJM, LEL, CHC, JPR, YW, DLN conducted the experiments. SAH, CA, AM, HD, CVH, OM,  
398 IZ conducted clinical investigation. CA, BJS, IZ analyzed the results. CA, BJS, EEG curated the  
399 data. SAH and CA visualized data and wrote the manuscript; all authors reviewed and edited the  
400 manuscript. SAH and PED supervised the study, and PED supervised all teams.

## 401 **Acknowledgments**

402 We are grateful to the following at LMIV: the Clinical Trials Team which includes Regina  
403 White, Alemush Imeru, and Kattie Khadar; the Data Manager Rathy Mohan; the Project  
404 Manager Sharon Wong-Madden. We thank Vu Nguyen, Richard Shimp, Jr., and Karine Reiter  
405 for oversight of the production and release of bulk conjugated vaccine. We also thank Holly  
406 McClellan and Weili Dai for their assistance in vaccine quality control evaluation. We are  
407 grateful for the work by Emily Kelnhofer and Ashley McCormack on the SMFA results; by Joan  
408 Aebig, Andrew Orcutt, and Sarah Brockley for ELISA data; by Nada Alani for isotyping  
409 ELISAs; and by Matthew Cowles for antibody purification. Thank you to NIH Clinical Center  
410 Outpatient Clinic 8 staff, in particular Karen Evans and Pam Stoll, and to NIH Clinical Center  
411 Pharmacy staff. Also, our appreciation to the extensive work completed by the LMIV animal  
412 team including Sachy Orr-Gonzalez, Brandi Butler, and Tarik Ouahes. In addition, we thank J.  
413 Patrick Gorres for assisting with writing, editing, and visualization.

414  
415 We thank the CRIMSON team at NIAID for providing assistance in the development and  
416 finalization of the case report forms and database. We thank OCRPRO for providing external  
417 monitoring services for this study and ongoing support and guidance to our NIAID programs,  
418 specifically Erin Rudzinski, Lisa Giebeig, Shelly Simpson, and Susan Vogel.

419  
420

421

## References

- 422 1. Bjorkman A, Shakely D, Ali AS, Morris U, Mkali H, Abbas AK, et al. From high to low  
423 malaria transmission in Zanzibar-challenges and opportunities to achieve elimination.  
424 *BMC Med.* 2019;17(1):14.
- 425 2. Cook J, Hergott D, Phiri W, Rivas MR, Bradley J, Segura L, et al. Trends in parasite  
426 prevalence following 13 years of malaria interventions on Bioko island, Equatorial  
427 Guinea: 2004-2016. *Malar J.* 2018;17(1):62.
- 428 3. WHO. Geneva, Switzerland: World Health Organization; 2019.
- 429 4. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Linkins J, Sutter RW, et al.  
430 Economic analysis of the global polio eradication initiative. *Vaccine.* 2010;29(2):334-43.
- 431 5. Fenner F. Risks and benefits of vaccinia vaccine use in the worldwide smallpox  
432 eradication campaign. *Res Virol.* 1989;140(5):465-6; discussion 87-91.
- 433 6. Riviere M, Tretiak R, Levinton C, Fitzsimon C, and Leclerc C. Economic benefits of a  
434 routine second dose of combined measles, mumps and rubella vaccine in Canada. *Can J*  
435 *Infect Dis.* 1997;8(5):257-64.
- 436 7. Carter R, and Chen DH. Malaria transmission blocked by immunisation with gametes of  
437 the malaria parasite. *Nature.* 1976;263(5572):57-60.
- 438 8. Gwadz RW. Successful immunization against the sexual stages of *Plasmodium*  
439 *gallinaceum*. *Science.* 1976;193(4258):1150-1.
- 440 9. Carter R, and Kaushal DC. Characterization of antigens on mosquito midgut stages of  
441 *Plasmodium gallinaceum*. III. Changes in zygote surface proteins during transformation  
442 to mature ookinete. *Mol Biochem Parasitol.* 1984;13(2):235-41.
- 443 10. Duffy PE, Pimenta P, and Kaslow DC. Pgs28 belongs to a family of epidermal growth  
444 factor-like antigens that are targets of malaria transmission-blocking antibodies. *J Exp*  
445 *Med.* 1993;177(2):505-10.
- 446 11. Grotendorst CA, Kumar N, Carter R, and Kaushal DC. A surface protein expressed  
447 during the transformation of zygotes of *Plasmodium gallinaceum* is a target of  
448 transmission-blocking antibodies. *Infect Immun.* 1984;45(3):775-7.
- 449 12. Barr PJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA, and Kaslow DC. Recombinant  
450 Pfs25 protein of *Plasmodium falciparum* elicits malaria transmission-blocking immunity  
451 in experimental animals. *J Exp Med.* 1991;174(5):1203-8.
- 452 13. Kapulu MC, Da DF, Miura K, Li Y, Blagborough AM, Churcher TS, et al. Comparative  
453 assessment of transmission-blocking vaccine candidates against *Plasmodium falciparum*.  
454 *Sci Rep.* 2015;5:11193.
- 455 14. Menon V, Kapulu MC, Taylor I, Jewell K, Li Y, Hill F, et al. Assessment of Antibodies  
456 Induced by Multivalent Transmission-Blocking Malaria Vaccines. *Front Immunol.*  
457 2017;8:1998.
- 458 15. Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, et al. Phase 1  
459 vaccine trial of Pvs25H: a transmission blocking vaccine for *Plasmodium vivax* malaria.  
460 *Vaccine.* 2005;23(24):3131-8.
- 461 16. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, et al. Phase 1 trial of  
462 malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with  
463 montanide ISA 51. *PLoS One.* 2008;3(7):e2636.
- 464 17. Talaat KR, Ellis RD, Hurd J, Hentrich A, Gabriel E, Hynes NA, et al. Safety and  
465 Immunogenicity of Pfs25-EPA/Alhydrogel(R), a Transmission Blocking Vaccine against

- 466 Plasmodium falciparum: An Open Label Study in Malaria Naive Adults. *PLoS One*.  
467 2016;11(10):e0163144.
- 468 18. Sagara I, Healy SA, Assadou MH, Gabriel EE, Kone M, Sissoko K, et al. Safety and  
469 immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against  
470 Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-  
471 escalation study in healthy Malian adults. *Lancet Infect Dis*. 2018;18(9):969-82.
- 472 19. MacDonald NJ, Nguyen V, Shimp R, Reiter K, Herrera R, Burkhardt M, et al. Structural  
473 and Immunological Characterization of Recombinant 6-Cysteine Domains of the  
474 Plasmodium falciparum Sexual Stage Protein Pfs230. *J Biol Chem*. 2016;291(38):19913-  
475 22.
- 476 20. Burkhardt M, Reiter K, Nguyen V, Suzuki M, Herrera R, Duffy PE, et al. Assessment of  
477 the impact of manufacturing changes on the physicochemical properties of the  
478 recombinant vaccine carrier ExoProtein A. *Vaccine*. 2018.
- 479 21. Shimp RL, Jr., Rowe C, Reiter K, Chen B, Nguyen V, Aebig J, et al. Development of a  
480 Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated  
481 nanoparticle. *Vaccine*. 2013;31(28):2954-62.
- 482 22. Quakyi IA, Carter R, Rener J, Kumar N, Good MF, and Miller LH. The 230-kDa gamete  
483 surface protein of Plasmodium falciparum is also a target for transmission-blocking  
484 antibodies. *J Immunol*. 1987;139(12):4213-7.
- 485 23. Read D, Lensen AH, Begarnie S, Haley S, Raza A, and Carter R. Transmission-blocking  
486 antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum  
487 gamete surface antigen Pfs230 are all complement-fixing. *Parasite Immunol*.  
488 1994;16(10):511-9.
- 489 24. Roeffen W, Geeraedts F, Eling W, Beckers P, Wizel B, Kumar N, et al. Transmission  
490 blockade of Plasmodium falciparum malaria by anti-Pfs230-specific antibodies is isotype  
491 dependent. *Infect Immun*. 1995;63(2):467-71.
- 492 25. Miura K, Swihart BJ, Deng B, Zhou L, Pham TP, Diouf A, et al. Transmission-blocking  
493 activity is determined by transmission-reducing activity and number of control oocysts in  
494 Plasmodium falciparum standard membrane-feeding assay. *Vaccine*. 2016;34(35):4145-  
495 51.
- 496 26. Healer J, McGuinness D, Carter R, and Riley E. Transmission-blocking immunity to  
497 Plasmodium falciparum in malaria-immune individuals is associated with antibodies to  
498 the gamete surface protein Pfs230. *Parasitology*. 1999;119 ( Pt 5):425-33.
- 499 27. Mendis KN, Munasinghe YD, de Silva YN, Keragalla I, and Carter R. Malaria  
500 transmission-blocking immunity induced by natural infections of Plasmodium vivax in  
501 humans. *Infect Immun*. 1987;55(2):369-72.
- 502 28. Stone W, Bousema T, Sauerwein R, and Drakeley C. Two-Faced Immunity? The  
503 Evidence for Antibody Enhancement of Malaria Transmission. *Trends Parasitol*.  
504 2019;35(2):140-53.
- 505 29. Radtke AJ, Anderson CF, Riteau N, Rausch K, Scaria P, Kelnhofer ER, et al. Adjuvant  
506 and carrier protein-dependent T-cell priming promotes a robust antibody response against  
507 the Plasmodium falciparum Pfs25 vaccine candidate. *Sci Rep*. 2017;7:40312.
- 508 30. Williamson KC, Keister DB, Muratova O, and Kaslow DC. Recombinant Pfs230, a  
509 Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity  
510 of Plasmodium falciparum to mosquitoes. *Mol Biochem Parasitol*. 1995;75(1):33-42.




- 511 31. Tsai CW, Duggan PF, Shimp RL, Jr., Miller LH, and Narum DL. Overproduction of  
512 *Pichia pastoris* or *Plasmodium falciparum* protein disulfide isomerase affects expression,  
513 folding and O-linked glycosylation of a malaria vaccine candidate expressed in *P.*  
514 *pastoris*. *J Biotechnol.* 2006;121(4):458-70.
- 515 32. Singh K, Burkhardt M, Nakuchima S, Herrera R, Muratova O, Gittis AG, et al. Structure  
516 and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-  
517 Pfs48/45 proteins. *Commun Biol.* 2020;3(1):395.
- 518 33. Scaria PV, Rowe CG, Chen BB, Muratova OV, Fischer ER, Barnafo EK, et al. Outer  
519 membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230.  
520 *NPJ Vaccines.* 2019;4:24.
- 521 34. Coelho CH, Tang WK, Burkhardt M, Galson JD, Muratova O, Salinas ND, et al. A high  
522 affinity human monoclonal antibody against Pfs230 binds multiple parasite stages and  
523 blocks oocyst formation in mosquitoes. 2020:2020.09.25.313478.
- 524 35. Duffy PE, and Kaslow DC. A novel malaria protein, Pfs28, and Pfs25 are genetically  
525 linked and synergistic as falciparum malaria transmission-blocking vaccines. *Infect*  
526 *Immun.* 1997;65(3):1109-13.  
527

528


529

## Figures


**Fig. 1. While (A) mouse studies comparing Pfs25-EPA/Alhydrogel® versus Pfs230D1-EPA/Alhydrogel® revealed no difference in immunogenicity or functional activity, (B) rhesus studies suggest Pfs230D1 is superior to Pfs25 and (C) requires active complement.** (A) Mouse sera samples collected after immunization with Pfs25-EPA/Alhydrogel® or Pfs230D1-EPA/Alhydrogel® were used in SMFA to measure antibody function. Each data point represents a pool of sera from one immunization group (n=10/grp). The titer shown in the x-axis is the titer in the mosquito feeder after dilution. (B) Rhesus monkey sera samples collected two weeks after the third immunization with Pfs25-EPA/Alhydrogel® or Pfs230D1-EPA/Alhydrogel® were used in SMFA to measure antibody function. Each data point represents an individual animal. The titer shown on the x-axis is the tier in the mosquito feeder after dilution. %TRA is relative to pre-bleed samples from each animal; (C) Sera from the Pfs230D1-EPA/Alhydrogel® group were divided in two for heat inactivation followed by SMFA.



**Fig. 2. Antibody titers by ELISA in humans.** Antibody titers from each vaccine arm. Vaccinations were performed on days 0 and 28 at escalating doses (n=5/arm).




**Fig. 3. Anti-Pfs230D1 has functional activity after 2 doses in humans.** Vaccination induces functional antibodies after 2 doses. Sera from subjects (n=5/grp) were collected 2 weeks after 2nd dose and used for SMFA. Each data point represents the oocyst count from one mosquito. n.p., naïve sera pool. \* p<0.05 difference from naïve pool, 15 pairwise Kruskal-Wallis tests with Bonferroni correction for multiple comparisons. Figure data are also represented in **Table S5**.



**Fig. 4. Functional activity of anti-Pfs230 requires active complement in humans.** Pfs230D1 requires complement for activity. Sera from subjects vaccinated with Pfs230D1-EPA/Alhydrogel or Pfs230D1-EPA+Pfs25-EPA/Alhydrogel were divided in two for complement inactivation and used for SMFA. Each data point represents the oocyst count from one mosquito. \*p<0.05 difference between post-vaccine and pre-bleed sera from individuals, Wilcoxon matched pairs signed-rank test with Bonferroni adjustment. Figure data are also represented in Table S6.

5



## **Supplementary Materials**

Human Study Objectives and Design

Figures S1-S7

Tables S1-S7